Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke

Pharmacogenomics Journal

Volumn 8, Issue 6, 2008, Pages 400-407

  Schelleman, H ^a,b   Klungel, O H ^b   Witteman, J C M ^a   Breteler, M M B ^a   Hofman, A ^a   van Duijn, C M ^a   de Boer, A ^b   Stricker, B H Ch ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN DERIVATIVE; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID; THYMIDINE;

AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE INTERACTION; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STROKE;

EID: 56349110470     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500493     Document Type: Article

References (11)

1. Brown MJ, Haydock S. Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000; 59(Suppl 2): 1-12.
2. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment. The Genetics of Hypertension-Associated Treatment (GenHAT) Study. Circulation 2005; 111: 3374-3383.
3. Benetos A, Cambien F, Gautier S, Richard S, Safar M, Laurent S et al Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-1084.
4. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin-system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13(12 Part 2): 1602-1609.
5. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
6. World Health Organization. International Classification of Diseases 10th revision (ICD-10). World Health Organization: Geneva, Switzerland, 1992.
7. Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: The Rotterdam study. Circulation 2002; 105: 2872-2877.
8. Anonymous. Guidelines for ATC Classification and DDD Assignment, 3rd edn. WHO Collaborating Centre for Drug Statistics Methodology: Oslo, Norway, 2000.
9. Van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes LM, Hofman A et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994; 7: 74-78.
10. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-711.
11. Khoury MJ, Flanders WD. Nontraditional epidemiological approaches in the analysis of gene-environment interaction: Case-control studies with no controls!. Am J Epidemiol 1996; 144: 207-213.